Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

Launched by NUTRACEUTICALS RESEARCH INSTITUTE · Apr 7, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the effects of a substance called Niagen®, which is an injectable form of a compound that may help with healthy aging. Researchers want to understand how well this injection works and how people feel after receiving it. The study is currently looking for participants who are healthy adults between the ages of 40 and 65, who do not engage in much exercise, and who have a specific body weight range. Participants must also be able to commit to the study and live within 100 miles of the research site.

If you join the study, you can expect to receive the injection and provide feedback on how you feel during the trial. It’s important to note that there are some health conditions that would exclude you from participating, such as certain chronic illnesses or recent significant changes in weight. Additionally, women who can become pregnant will need to use effective contraception during the study. Overall, this trial aims to gather valuable information about Niagen® and its potential benefits for healthy aging.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Provision of signed and dated informed consent form
• • Stated willingness and demonstrated ability to comply with all study procedures, as well as availability for the duration of the study
• • Lives within 100 miles of the NRI study site
• • Any gender, aged 40-65, inclusive
• • Good general health as evidenced by medical history
• • BMI 25-34.9 kg/m2
• • Sedentary behavior (defined as \<20 minutes per day or 100 minutes per week of moderate to vigorous exercise)
• • Demonstrated fatigue (Fatigue Assessment Scale) defined as a below-average score
• • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of the study
• • Agreement to adhere to Lifestyle Considerations throughout study duration
• Exclusion Criteria:
• • Current diagnosis of any seizure disorder, diabetes or insulin resistance, any kidney or liver disorder, heart disease, anemia, cancer, or Parkinson's disease
• • ANY chronic illness (pre-disease state acceptable)
• • Out of range phosphate levels at baseline
• • BMI less than 25 or greater than or equal to 35
• • Pregnancy, trying to conceive, or breastfeeding
• • Known allergic reactions to any components of the intervention or related compounds, including any form of B3
• • Positive COVID-19 test within 30 days of the study period
• • Recent dramatic weight changes (10% change in body weight in the last 6 months)
• • Existing usage of a NAD+ or NAD precursor supplement in any form (oral, nasal, patch, or injection/IV administration), including a B-complex supplement, within 60 days of the study, not including multivitamins.
• • Introducing a new medication, supplement, investigational drug, or other intervention (including lifestyle changes) within 60 days of the start of the study.